Navigation Links
PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust
Date:12/22/2011

SOUTH PLAINFIELD, N.J., Dec. 22, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria.  PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The discovery and development of new and novel antibiotics are urgently needed due to the increased frequency of bacterial resistance to marketed antibiotics in the hospital and community settings.  Hospital-acquired infections present a major threat to patient health and quality of life.  The Centers for Disease Control and Prevention estimates that approximately 1.7 million hospital-acquired bacterial infections cause or contribute to nearly 100,000 deaths in the United States each year with similar data reported from Europe.  Gram-negative bacteria are responsible for more than 30 percent of these infections.  The major concern with MDR Gram-negative bacteria is there are limited options to effectively treat them.

"We are honored to expand our relationship with the Wellcome Trust through this second award," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer at PTC Therapeutics.  "This funding will support our ongoing efforts to develop novel antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria."

PTC has identified a novel structural class of molecules that have potent activity against Gram-negative bacteria that are resistant to marketed antibiotics.  The anti-infective program at PTC is currently in lead optimization and advancing towards identifying a Development Candidate.

About Wellcome Trust

The Wellcome Trust is a global charity dedicated to achieving extraordinary improvements in human and animal health.  It supports the brightest minds in biomedical research and the medical humanities.  The Trust's breadth of support includes public engagement, education and the application of research to improve health.  It is independent of both political and commercial interests. www.wellcome.ac.uk

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company that applies its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious and life-threatening conditions.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology, and infectious diseases.  PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
2. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
3. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
4. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
5. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
6. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
7. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
8. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
9. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
10. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
11. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance Company ... life insurance throughout various life stages. , The site launched on April 1, ... and content specific to the times when life insurance matters most. , “Through ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident Matching Program® ... Match® (“the Match”), the system through which U.S. and international medical school students ... positions were placed in the 2016 Match, and 29,572 were filled when the ...
(Date:5/2/2016)... NY (PRWEB) , ... May 02, 2016 , ... Over ... the year’s best in pet gear and toys, leading product review site for Toys, ... Paw of Excellence Awards at their Spring Showcase at the Metropolitan Pavilion in ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):